Fibrin Sealants Market size is estimated to reach USD 1780 million by the end of 2033, growing at a CAGR of 6% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of fibrin sealants was over USD 885 million. The growth of the market is primarily attributed to the growing prevalence of several kinds of surgeries, the growing occurrence of blood disorders, and traumatic injuries across the globe. As per the figures provided by the World Health Organization (WHO), each year, 3.16 million individuals die as a consequence of unintentional injuries, while 1.25 million individuals die as a consequence of violence-related injuries on a worldwide level.
Fibrin sealants (FS) are protein-based medical adhesives that aid in wound closure and healing. Though bovine and porcine sources are also available, fibrin sealants are generally extracted from human blood. The fibrin sealant molecule's adhesive characteristics allow it to quickly form a clot at the site of the incision, preventing bleeding and sealing it. Fibrin sealant has also been proven to speed up epithelial cell migration, which promotes faster rates of tissue regeneration. For instance, in a clinical study, it was observed that the use of fibrin sealant in combination with photo-biomodulation therapy has shown promising outcomes in the repair of peripheral nerve injuries, as well as being efficient in the neurorrhaphy process and providing a higher quality of axonal regeneration to the interior of the distal stump.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 885 Million |
|
Forecast Year Market Size (2033) |
~ USD 1780 Million |
|
Regional Scope |
|
Application (General Surgery, Cardiovascular Surgery, Thoracic Surgery, Orthopedic Surgery, Transplant Surgery, Neurosurgery, Dental Surgery, Wound Management)
The global fibrin sealants market can be further divided based on application into cardiovascular surgery, thoracic surgery, orthopedic surgery, neurosurgery, dental surgery, wound management, transplant surgery, and others. Cardiovascular Surgery had a sizable market share in 2021 and is anticipated to increase at the quickest rate over the forecast period. Cardiovascular surgery, also referred to as heart surgery, is a type of surgery that involves operating on the heart to treat serious health issues. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) account for 17.9 million deaths per year, or 32% of all fatalities worldwide, making them the leading cause of death globally. Fibrin sealants are used in cardiovascular surgery to reduce the need for blood and blood product transfusions, improve hemostasis in heparin-treated patients, and control problematic bleeding on vascular anastomoses through tissue sealing. According to estimates, the market for cardiovascular procedures will grow as the number of cardiovascular illnesses rises. One in four fatalities in the United States occurs as a result of heart disease, according to the Centers for Disease Control and Prevention (CDC), which is what is causing the segment to rise.
Type (Liquid, Patch, Powder)
The global fibrin sealant market is segmented and analyzed by type into liquid, patch, and power. Out of the three types, the liquid segment is estimated to gain the largest market share over the projected time frame. This can be attributed to the better procedural results than the patch, and powder type. Furthermore, the quick action and higher rational stability of liquid solutions are expected to propel this market even further. Moreover, the fact that the fibrin sealant patch can achieve hemostasis 3–4 minutes after the application is one of its key benefits. Therefore, it is anticipated to boost the segment’s growth in the region.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Technology |
|
|
By End-User |
|
North American Market Forecast
The North America fibrin sealants market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033, backed by the significantly increasing healthcare expenditure, growing occurrence of cardiovascular diseases, and growing count of surgical procedures in the region. According to the surveys, cardiovascular disease is the leading cause of death in the United States, taking one life every 36 seconds and fostering the growth of the fibrin sealant industry.
Due to its sophisticated healthcare system, extensive use of cutting-edge automated analyzers, and sizable target patient population, the US now has a prominent position in the North American fibrin sealant industry. For instance, Sysmex Corporation unveiled the blood coagulation analyzers CN-6000 and CN-3000 in 2018, which are next-generation analyzers in the hemostasis area.
APAC Market Statistics
Additionally, a large concentration of pharmaceutical and biotechnology firms, as well as developing health infrastructure, are fueling the market’s growth for fibrin sealants in the Asia Pacific region. Furthermore, owing to their technologically advanced healthcare systems, novel treatment procedures, and sizable patient populations, China, Japan, and South Korea are considered to be the most lucrative markets in the Asia Pacific region. These countries are predicted to dominate the market in the region in terms of revenue share and expand at a much faster rate than other countries.
Europe Market Forecast
Moreover, market in the Europe region is also expected to have a significant growth over the forecast period, backed by the increasing fibrin sealant sales followed by an increase in cases of various dental problems. Europe's market is currently controlled by countries such as the UK, Germany, Italy, and France. Most people with dentures suffer with confidence, according to a UK survey, as they find it uncomfortable to put loose-fitting dentures in their mouths. In the UK, the market for dental sealants is anticipated to increase significantly throughout the anticipated period owing to the rapidly rising prevalence of dental and oral problems such as tooth decay and periodontal flap closure as well as the rising need for cosmetics. This is majorly owing to the adoption of more advanced and cutting-edge sealant products.
Asahi Kasei Corporation has acquired Bionova Scientific, LLC, a provider of contract process development and GMP-compliant contract manufacturing services to the biopharmaceutical industry.
Grifols S.A. launched VISTASEAL plasma-protein-based bleeding-control solutions. Using Ethicon's airless spray device technology, this medication combines fibrinogen and thrombin, two plasma proteins.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?